Alzheon has 3 close competitors: Quince, Biosplice Therapeutics, Alloy Therapeutics.
Sector, valuation and status for each competitor.
A private valuation and a public market cap share one column; each row names its basis and date.
Alzheon
Quince
Biosplice TherapeuticsBiopharmaceutical company focused on Alzheimer's disease
Alzheon competes with 3 companies here: Quince, Biosplice Therapeutics, Alloy Therapeutics.
Alzheon was last valued at $1.3B . That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
Lead investors for each round are in the funding timeline.
The closest biopharmaceutical peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Alzheon is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
